Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Atossa Therapeutics Inc
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
February 19, 2026
Atossa Therapeutics’ Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
January 21, 2026
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
January 17, 2026
Atossa Therapeutics Receives FDA “Study May Proceed” Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
January 6, 2026
←
Previous Page
1
2